KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Long-Term Deferred Tax: 2010-2024

Historic Long-Term Deferred Tax for Biomarin Pharmaceutical (BMRN) over the last 15 years, with Dec 2024 value amounting to $1.5 billion.

  • Biomarin Pharmaceutical's Long-Term Deferred Tax fell 1.42% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year decrease of 1.42%. This contributed to the annual value of $1.5 billion for FY2024, which is 3.65% down from last year.
  • According to the latest figures from FY2024, Biomarin Pharmaceutical's Long-Term Deferred Tax is $1.5 billion, which was down 3.65% from $1.5 billion recorded in FY2023.
  • In the past 5 years, Biomarin Pharmaceutical's Long-Term Deferred Tax registered a high of $1.5 billion during FY2023, and its lowest value of $1.4 billion during FY2020.
  • For the 3-year period, Biomarin Pharmaceutical's Long-Term Deferred Tax averaged around $1.5 billion, with its median value being $1.5 billion (2022).
  • In the last 5 years, Biomarin Pharmaceutical's Long-Term Deferred Tax surged by 160.66% in 2020 and then dropped by 3.65% in 2024.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Long-Term Deferred Tax stood at $1.4 billion in 2020, then climbed by 1.26% to $1.5 billion in 2021, then grew by 3.81% to $1.5 billion in 2022, then climbed by 2.68% to $1.5 billion in 2023, then decreased by 3.65% to $1.5 billion in 2024.